Status:
COMPLETED
Long-term Safety and Tolerability of AFFITOPE AD02
Lead Sponsor:
Affiris AG
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Brief Summary
The purpose of this study is to evaluate the long-term tolerability and -safety of AFFITOPE AD02 applied during AFFiRiS 002
Eligibility Criteria
Inclusion
- Written informed consent signed and dated by patient and caregiver
- Patients having participated in AFF002 and having received at least 1 vaccination with AFFITOPE AD02
- Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits
Exclusion
- Patients having received no vaccination with AFFITOPE AD02
- History of questionable compliance to visit schedule, patients not expected to finish the clinical trial
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00711321
Start Date
November 1 2008
End Date
April 1 2010
Last Update
May 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ordination Schmitz
Vienna, Austria, 1010